Get in touch today 206.598.4100 or

Schedule an Appointment

Yolanda Tseng, M.D.

Assistant Professor

Locations of Practice

SCCA Proton Therapy

1570 N 115th Street
Seattle, WA 98133

Locate on Google Maps

Overview

A recent graduate of Harvard University Medical School and their radiation oncology residency program, Dr. Tseng believes that cancer is best treated with a team approach that includes other physicians, nurses, and technical staff involved in treatment planning. She has conducted research in diverse areas, including how physicians estimate patient prognosis and its effects on treatment decisions, and how tumor biological subtypes affect patient outcomes and the response to local therapy. She is interested in systematically evaluating how proton radiotherapy can be used to optimize patient care. “As treatment efficacy improves for many disease sites, the goal now is to minimize the long-term side effects of our treatments. My hope is that we can achieve this for our patients.”

Patient Care Philosophy

One of the most anxious times during a cancer diagnosis is determining the plan of action. This requires a team approach, in which both patient and physician learn from each other about their priorities, goals, and expectations. It is important for my patients to feel well informed about their treatment options, since this allows us to make the best decision together about their care.

Education and Training

College:  Cornell University, Ithaca, NY, 2003

Graduate School: University of Cambridge, M.Phil., Cambridge, UK 2004

Medical Education: Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 2009

Internship: Internal Medicine, Brigham and Women’s Hospital, Boston, MA 2010

Residency: Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA 2014

Published Works

Takagishi SR, Marx TE, Lewis C, Shantha E, Juhlin I, Blom A, Iyer JG, Liao JJ, Tseng YD, Nghiem P, Parvathaneni U.
Post operative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck.
Advances in Radiation Oncology (in press).

Hoppe BS, Tsai H, Larson G, Laramore GE, Vargas C, Tseng YD, Dunn M, McGee L, Cahlon O, Hartsell W.
Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry.
Acta Oncol. 2016 Nov;55(11):1378-1380. PMID: 27579554

Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS.
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):622-30. doi: 10.1016/j.ijrobp.2015.07.006. PMID: 26461004

Tseng YD, Chen Y, Catalano P, Ng A. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):223-31. doi: 10.1016/j.ijrobp.2014.09.041.

Balboni MJ, Sullivan A, Enzinger AC, Epstein-Peterson ZD, Tseng YD, Mitchell C, Niska J, Zollfrank A, Vanderweele TJ, Balboni TA. Nurse and physician barriers to spiritual care provision at the end of life. J Pain Symptom Manage 2014; 48(3): 400-10. PMID: 24480531.

Tseng YD, Krishnan M, Jones JA, Sullivan AJ, Gorman D, Taylor A, Pacold M, Kalinowski B, Mamon HJ, Abrahm J, Balboni TA. The supportive and palliative radiation oncology service: impact of a dedicated service on palliative cancer care. Pract Radiat Oncol 2014; 4(4): 247-53. PMID: 25012833.

Krishnan M, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer 2014; 120(1):134-41. PMID: 24122413.

Tseng YD, Paciorek AT, Martin NE, D’Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer 2014; 120(6):824-32. PMID: 24301555.

Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Castillo CF, Hong TS. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol 2014; 110(1); 160-4. PMID: 24231241.

Tseng YD and Martin NE. How can I help myself? A critical review of modifiable behaviors, medications, and complementary alternative medicine for men receiving radiotherapy for prostate cancer. Semin Radiat Oncol 2013; 23(3): 173-81. PMID: 23763883.

Board Certification

American Board of Radiology, 2015